Collegium Needs Jornay And Astaris To Outrun A Fading Nucynta Franchise

Collegium Pharmaceutical heads into its third-quarter report with a business that is splitting in two. Its ADHD franchise is gaining share and just added a freshly integrated acquisition, while its legacy pain portfolio, the cash engine that funded the pivot, is eroding faster than management planned. The stock has lost more than a quarter of its value since the last report, so the question is whether the growth side can show enough muscle during the critical back-to-school season to convince investors the decline in pain is a manageable transition rather than a slow leak.

Wall Street expects earnings of $1.53 per share on revenue of about $215.0 million. That is only 2.7% revenue growth from a year ago, while earnings are projected to fall roughly 26% from $2.06. Much of that gap reflects the cost of growth. Net leverage climbed to about 2.1 times after the Astaris deal closed in May, up from under 1 times at the end of 2025, and the heavier debt load is one reason profits may lag the top line. Management's full-year revenue range sits at $825 million to $855 million, and adjusted EBITDA guidance was trimmed last quarter to $445 million to $470 million, essentially flat with 2025. The full-year revenue consensus of roughly $864 million sits above the top of the company's range, which suggests some estimates have not fully absorbed the reset and leaves room for disappointment if management merely holds its outlook.

The bull case rests on Jornay and Astaris. Jornay revenue rose 41% last quarter to $46.1 million, prescribers topped 30,000 for the first time, and its share of the branded long-acting methylphenidate market climbed to 29.2%, extending a steady march from 23.4% a year earlier. The third quarter is when back-to-school prescribing should show whether that momentum translates into a step change. Another share gain and a comfortable path toward the $190 million to $200 million Jornay target would validate the story. Astaris also faces its first real test. Management raised its 2026 contribution to $65 million to $75 million and said salesforce training was finished ahead of the school season, so this is the quarter where that confidence should start appearing in the numbers.

The risk lies in the pain business. Nucynta revenue fell 24% last quarter to $35.2 million after authorized-generic pricing came in far below plan, with the immediate-release version netting only 10% to 15% of the branded price. Xtampza slipped 14% on pressure across branded long-acting opioids and a tough rebate comparison. Investors need evidence that Nucynta pricing has found a floor and that Xtampza's decline was partly a timing quirk. Belbuca, up 10% with new formulary access for 9 million lives starting in the fourth quarter, offers some offset, though its potential generic exposure beginning in January 2027 limits how much credit it earns.

Sentiment has cooled noticeably, with bullish readings falling from 17.0% before the last report to 4.8% now. The stock, at $23, trades well below its 200-day moving average near $33.65 and only modestly above its post-earnings low of $21.43, a sharp comedown from the $30 to $40.50 range of the prior quarter. That pessimism lowers the bar on sentiment, but not on the numbers, given that full-year estimates still sit above guidance.

Ultimately, this report comes down to whether Collegium can hold its trimmed EBITDA outlook without another legacy cut. Strong Jornay share and an on-track Astaris ramp paired with stable Nucynta pricing would restore credibility to the diversification thesis. Another downward revision to the pain base would suggest the growth assets are still running behind the erosion they were meant to replace.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.